Financial Data and Key Metrics Changes - Adjusted diluted EPS increased by 9% to $4.08, driven by strong performance in the US Healthcare Solutions segment [15][16] - Consolidated revenue reached $85.9 billion, up 5.5%, attributed to growth in both reportable segments [15][16] - Consolidated gross profit was $3.0 billion, an 18% increase, with a gross profit margin of 3.48%, up 37 basis points [16] - Operating income rose by 12% to $1.1 billion, reflecting strong execution and growth in the US Healthcare Solutions segment [16][19] Business Line Data and Key Metrics Changes - US Healthcare Solutions revenue was $76.2 billion, up 5%, with operating income increasing by 21% to $831 million [19][20] - International Healthcare Solutions revenue was $7.6 billion, up approximately 10% on an as-reported basis, but operating income decreased by 14% [20][21] - Revenue in Other was $2.1 billion, up 6%, primarily due to growth at MWI Animal Health and ProPharma [22] Market Data and Key Metrics Changes - Strong sales growth in the US for GLP-1 products increased by $1 billion or 11% over the prior year quarter [15][16] - International Healthcare Solutions segment faced challenges due to timing of manufacturer price adjustments in a developing market country [21][57] Company Strategy and Development Direction - The company completed the acquisition of One Oncology, enhancing its capabilities in community oncology and supporting its pharmaceutical-centric strategy [5][14] - Three growth priorities include strengthening leadership in specialty, leading with market leaders, and enhancing patient access to pharmaceuticals [7][12] - The MSO expansion is seen as a natural extension of the company's leadership in specialty pharmaceuticals, aiming to unlock new opportunities [8][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term guidance for adjusted operating income growth in the US, now expected to be 14%-16% [35][36] - The company anticipates continued strength in the US Healthcare Solutions segment, driven by utilization trends and specialty sales [35][71] - Management noted that the international segment is expected to rebound, maintaining guidance for adjusted operating income growth of 5%-8% for the fiscal year [57] Other Important Information - The company has paused share repurchases to prioritize debt paydown following the One Oncology acquisition [17][29] - Adjusted free cash flow for the quarter was negative $2.4 billion, with expectations of approximately $3 billion for the full year [18] Q&A Session Summary Question: Clarification on operating income growth and deceleration - Management clarified that adjusted operating income growth in the US was 21% in the December quarter, and guidance for the full year has been increased to 14%-16% [33][35] Question: Opportunities in the MSO platform for AOI growth - Management highlighted short-term and long-term opportunities in leveraging clinical trial excellence and revenue cycle management across the MSO platforms [39][41] Question: Impact of strategic partnerships with health systems - Management emphasized the importance of relationships with health systems and the expected growth from these partnerships [45][46] Question: Timing dynamics in the international segment - Management explained that the international segment faced a timing issue with manufacturer price adjustments, but expects a rebound in performance [56][57] Question: Revenue guidance changes and One Oncology contribution - Management noted that One Oncology's impact on revenue guidance is limited due to its lower revenue business model but contributes positively to operating income [80][81]